dr-_peter_reckenthaler-and-dr-_romina_kuhnle
19 January 2023BiotechnologyStaff Writer

Cohausz & Florack hires senior technical duo

Cohausz & Florack (C&F) has added two new partners to the team, Romina Kühnle and Peter Reckenthäler.

The appointments further expand the firm’s IP expertise in key technical areas.

Kühnle is an expert in the fields of chemistry, materials science, pharmaceuticals, and life sciences, with particular experience in polymer chemistry, materials and pharmaceutical chemistry.

After studying chemistry at the Philipps-Universität Marburg specialising in polymer chemistry, she completed her doctorate at the Max Planck Institute of Colloids and Interfaces in Potsdam and at the Humboldt-Universität zu Berlin in the field of self-organisation of peptide-polymer conjugates.

She has been a patent attorney at C&F since 2017 and had previously completed her patent attorney training at the firm. “Awareness of the importance of pharmaceutical and chemical research has risen significantly in our society in recent years.

“The field of chemistry & life sciences is also growing in importance for us as a firm,” said Natalie Kirchhofer, patent attorney and partner at C&F. “We are delighted to be able to further strengthen and build on this area with Romina Kühnle as a partner and established expert.”

Peter Reckenthäler holds a PhD in physics and is a member of C&F’s electrical engineering team, where he primarily advises clients from the mobile communications sector.

He studied physics at the Friedrich-Wilhelms-Universität in Bonn and at the Universidad Autónoma de Madrid (Spain) and held a scholarship at the International Max Planck Research School of Advanced Photon Science.

His technical expertise includes general physics, optics, laser technology, and the field of semiconductors and LEDs.

Reckenthäler worked for several years in renowned Munich firms before joining the C&F team as a patent attorney in 2019, and has now also been named a partner.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox


More on this story

Generics
4 November 2021   Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.

More on this story

Generics
4 November 2021   Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.